Orion Oyj (OTCMKTS:ORINY - Get Free Report)'s stock price reached a new 52-week high during trading on Wednesday . The company traded as high as $36.45 and last traded at $36.45, with a volume of 236 shares traded. The stock had previously closed at $35.72.
Orion Oyj Stock Performance
The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41. The business has a 50-day moving average of $30.97 and a 200-day moving average of $27.68. The company has a market capitalization of $10.29 billion, a P/E ratio of 28.93 and a beta of 0.07.
Orion Oyj (OTCMKTS:ORINY - Get Free Report) last released its earnings results on Wednesday, April 23rd. The company reported $0.23 earnings per share for the quarter. The company had revenue of $373.03 million for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. On average, sell-side analysts anticipate that Orion Oyj will post 1.18 EPS for the current year.
Orion Oyj Increases Dividend
The company also recently disclosed a dividend, which was paid on Tuesday, April 29th. Investors of record on Monday, April 7th were issued a $0.4478 dividend. The ex-dividend date was Monday, April 7th. This is a boost from Orion Oyj's previous dividend of $0.24. Orion Oyj's dividend payout ratio (DPR) is 24.43%.
Orion Oyj Company Profile
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
Recommended Stories
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
